) has been revised to $30.00 / share. This is a decrease of 30.94% from the prior estimate of $43.45 dated February 1, 2026. The price target is an average of many targets provided by analysts. The ...
What To Know: While Hims & Hers doesn’t manufacture the GLP-1 drugs, a class of medications that help manage Type 2 diabetes and obesity, like Eli Lilly’s Zepbound and Novo Nordisk’s Ozempic, it sells ...
Last Thursday, Hims & Hers Health announced an expansion of its weight loss specialty by enabling providers to prescribe a Compounded Semaglutide Pill with the same active ingredient as Novo Nordisk’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results